Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Alto Neuroscience, Inc. Common Stock (NY:ANRO)

13.43 +0.05 (+0.37%)

Official Closing Price Updated: 7:00 PM EST, Dec 5, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	206,643
Open	13.46
Bid (Size)	13.10 (100)
Ask (Size)	13.91 (100)
Prev. Close	13.38
Today's Range	12.95 - 13.71
52wk Range	1.600 - 16.49
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08

December 03, 2025

From Alto Neuroscience, Inc.

Via Business Wire

Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗

November 17, 2025

Via Benzinga

Performance

YTD	+206.6%	+206.6%
1 Month	+19.0%	+19.0%
3 Month	+265.9%	+265.9%
6 Month	+422.6%	+422.6%
1 Year	+244.4%	+244.4%

More News

This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

November 17, 2025

Via Benzinga

Alto Neuroscience Inc (NYSE:ANRO) Reports Narrower Q3 2025 Loss and Accelerated Pipeline Progress ↗

November 12, 2025

Via Chartmill

Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 12, 2025

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience to Participate in Upcoming Investor Conferences

October 28, 2025

From Alto Neuroscience, Inc.

Via Business Wire

These stocks are moving in today's session ↗

October 20, 2025

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 20, 2025

Via Benzinga

Top movers analysis in the middle of the day on 2025-10-20: top gainers and losers in today's session. ↗

October 20, 2025

Via Chartmill

Gapping stocks in Monday's session ↗

October 20, 2025

Via Chartmill

Alto Neuroscience Announces $50 Million Private Placement Financing

October 20, 2025

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

October 20, 2025

From Alto Neuroscience, Inc.

Via Business Wire

ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

October 07, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 03, 2025

Via Benzinga

Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug ↗

October 03, 2025

Via Stocktwits

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

October 03, 2025

From Alto Neuroscience, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 02, 2025

Via Benzinga

This Electronic Arts Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗

September 29, 2025

Via Benzinga

This VSE Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

September 29, 2025

Via Benzinga

Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Brainstorm Cell Therapeutics Inc. (OTC: BCLI); Flywire Corporation (NASDAQ: FLYW); and Ibotta, Inc. (NYSE: IBTA): Grabar Law Office is Investigating Claims on Your Behalf

September 22, 2025

From Grabar Law Office

Via GlobeNewswire

Alto Neuroscience, Inc. Class Action: Levi & Korsinsky Reminds Alto Neuroscience, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 19, 2025 - ANRO

September 19, 2025

Via TheNewswire.com

Alto Neuroscience, Inc. Class Action: Levi & Korsinsky Reminds Alto Neuroscience, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 19, 2025 - ANRO

September 19, 2025

Via NewMediaWire

ANRO FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Alto Neuroscience, Inc. (ANRO) of the September 19th Deadline

September 19, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Investors Who Lost Money on Alto Neuroscience, Inc. (ANRO) Should Contact Levi & Korsinsky About Pending Class Action - ANRO

September 18, 2025

Via TheNewswire.com

Investors Who Lost Money on Alto Neuroscience, Inc. (ANRO) Should Contact Levi & Korsinsky About Pending Class Action - ANRO

September 18, 2025

Via NewMediaWire

Frequently Asked Questions

Is Alto Neuroscience, Inc. Common Stock publicly traded?

Yes, Alto Neuroscience, Inc. Common Stock is publicly traded.

What exchange does Alto Neuroscience, Inc. Common Stock trade on?

Alto Neuroscience, Inc. Common Stock trades on the New York Stock Exchange

What is the ticker symbol for Alto Neuroscience, Inc. Common Stock?

The ticker symbol for Alto Neuroscience, Inc. Common Stock is ANRO on the New York Stock Exchange

What is the current price of Alto Neuroscience, Inc. Common Stock?

The current price of Alto Neuroscience, Inc. Common Stock is 13.43

When was Alto Neuroscience, Inc. Common Stock last traded?

The last trade of Alto Neuroscience, Inc. Common Stock was at 12/05/25 07:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.